Clinical guidelines &quot;Migraine&quot;

Azimova Yu.E.; Amelin A.V.; Alferova V.V.; Artemenko A.R.; Akhmadeeva L.R.; Golovacheva V.A.; Danilov A.B.; Ekusheva E.V.; Isagulyan E.D.; Koreshkina M.I.; Kurushina O.V.; Latysheva N.V.; Lebedeva E.R.; Naprienko M.V.; Osipova V.V.; Pavlov N.A.; Parfenov V.A.; Rachin A.P.; Sergeev A.V.; Skorobogatykh K.V.; Tabeeva G.R.; Filatova E.G.

doi:https://doi.org/10.17116/jnevro20221220134

Azimova Yu.E.

Scientific Research Institute of General Pathology and Pathophysiology;
University Headache Clinic

SPIN RSCI: 6802-3979
Scopus AuthorID: 23494670700
ORCID: 0000-0002-3713-4884

Amelin A.V.

Pavlov First Saint Petersburg State Medical University

SPIN RSCI: 2402-7452
Scopus AuthorID: 7007120162
ORCID: 0000-0001-6437-232X

Alferova V.V.

Artemenko A.R.

SPIN RSCI: 7962-7886
Scopus AuthorID: 7004389945
ORCID: 0000-0002-6219-3384

Akhmadeeva L.R.

Bashkir State Medical University

ORCID: 0000-0002-1177-6424

Golovacheva V.A.

Danilov A.B.

Sechenov First Moscow State Medical University (Sechenov University)

Ekusheva E.V.

Academy of Postgraduate Education under the Federal State Budgetary Unit «Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency»;
Belgorod State National Research University

SPIN RSCI: 8828-0015
Scopus AuthorID: 6507964640
ORCID: 0000-0002-3638-6094

Isagulyan E.D.

Burdenko Neurosurgical Center

ORCID: 0000-0003-1191-9357

Koreshkina M.I.

Headache Treatment Center Scandinavia

Kurushina O.V.

Volgograd State Medical University

SPIN RSCI: 4571-5646
Scopus AuthorID: 37008504700
ORCID: 0000-0003-4364-0123

Latysheva N.V.

Sechenov First Moscow State Medical University (Sechenov University);
Alexander Vein Headache Clinic

SPIN RSCI: 9303-1000
Scopus AuthorID: 24492160100
ORCID: 0000-0001-9600-5540

Lebedeva E.R.

Ural State Medical University;
International Headache Centre «Europe-Asia»

ORCID: 0000-0003-2463-7113

Naprienko M.V.

Sechenov First Moscow State Medical University (Sechenov University);
Alexander Vein Headache Clinic

SPIN RSCI: 9109-8980
Scopus AuthorID: 7801550358
ORCID: 0000-0003-4204-2279

Osipova V.V.

Pavlov N.A.

Research and Practical Clinical Center for Diagnostic and Telemedicine Technologies

ORCID: 0000-0002-4309-1868

Parfenov V.A.

Sechenov First Moscow State Medical University

SPIN RSCI: 3322-5559
Scopus AuthorID: 57216913889
ResearcherID: AAG-7021-2019
ORCID: 0000-0002-1992-7960

Rachin A.P.

National Research Medical Center for Rehabilitation and Balneology

ORCID: 0000-0003-4266-0050

Sergeev A.V.

N. Bekhtereva Institute of Human Brain Russian Academy of Sciences

ORCID: 0000-0002-6391-3240

Skorobogatykh K.V.

«University Headache Clinic» LLC

SPIN RSCI: 5960-2556
Scopus AuthorID: 55920745300
ORCID: 0000-0002-1279-9548

Tabeeva G.R.

Sechenov First Moscow State Medical University

Filatova E.G.

Sechenov First Moscow State Medical University (Sechenov University);
Alexander Vein Headache Clinic

SPIN RSCI: 9172-7932
Scopus AuthorID: 7004339469
ORCID: 0000-0001-9978-4180

Clinical guidelines "Migraine"

Authors:

Azimova Yu.E., Amelin A.V., Alferova V.V., Artemenko A.R., Akhmadeeva L.R., Golovacheva V.A., Danilov A.B., Ekusheva E.V., Isagulyan E.D., Koreshkina M.I., Kurushina O.V., Latysheva N.V., Lebedeva E.R., Naprienko M.V., Osipova V.V., Pavlov N.A., Parfenov V.A., Rachin A.P., Sergeev A.V., Skorobogatykh K.V., Tabeeva G.R., Filatova E.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1‑3): 4‑36

DOI: 10.17116/jnevro20221220134

Read: 57795 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Azimova YuE, Amelin AV, Alferova VV, et al. . Clinical guidelines "Migraine". S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1‑3):4‑36. (In Russ.)
https://doi.org/10.17116/jnevro20221220134

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

References:

Amelin AV, Ignatov YuD, Skoromets AA, Sokolov AYu. Migraine (pathogenesis, clinic, treatment). Moscow: Medpress; 2011. (In Russ.).
Osipova VV, Tabeeva GR. Primary headaches: diagnosis, clinic, therapy. A practical guide. Moscow: Medical Information Agency Publishing House; 2014. (In Russ.).
Tabeeva GR, Yakhno NN. Migraine. Moscow: GEOTAR-Media; 2011. (In Russ.).
Sergeev AV, Tabeeva GR, Azimova UE. Central neuronal hyperexcitability - a predisposition to migraine. Russian Journal of Pain. 2010;2(27):3-11. (In Russ.).
Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population — a prevalence study. J Clin Epidemiol. 1991;44:1147-1157.
Ayzenberg I, Katsarava Z, Sborowski A, et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia. 2012;32(5):373-381.
Lebedeva ER, Kobzeva NR, Gilev DV, Olesen Es. Analysis of the quality of diagnosis and treatment of primary headaches in different social groups of the Ural region. Neurology, neuropsychiatry, and psychosomatics. 2015;1:19-26. (In Russ.).
The International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia. 2018;38(1):1-211.
Osipova VV. Migraine and tension headache. Clinical guidelines. Neurology and Neurosurgery. Edited by Gusev Ye.I., Konovalov A.N. 2nd ed. revised and supplemented. M.: GEOTAR-Media; 2015. (In Russ.).
Li D, Christensen AF, Olesen J. Field-testing of the ICHD-3 beta/proposed ICD-11 diagnostic criteria for migraine with aura. Cephalalgia. 2015;35(9):748-756.
Lebedeva ER, Gurary NM, Gilev DV, Olesen J. Prospective testing of ICHD-3 beta diagnostic criteria for migraine with aura and migraine with typical aura in patients with transient ischemic attacks. Cephalalgia. 2018;38(3):561-567.
Lebedeva ER, Gurary NM, Gilev DV, et al. Explicit diagnostic criteria for transient ischemic attacks to differentiate it from migraine with aura. Cephalalgia. 2018;38(8):1463-1470.
Ekusheva EV, Karpova MI, Osipova VV. Hormonal contraceptives and the risk of ischemic stroke in women with migraine: a new international consensus. Neurology, neuropsychiatry, and psychosomatics. 2019;11(3):11-15. (In Russ.).
Artemenko AR, Kurenkov AL, Belomestova KV Classification, diagnosis and treatment of chronic migraine: a review of new data. Journal of Neurology and Psychiatry. S.S. Korsakov. 2013;11:91-96. (In Russ.).
Osipova VV, Filatova EG, Artemenko AR, et al. Diagnosis and treatment of migraine: recommendations of Russian experts. Journal of Neurology and Psychiatry. S.S. Korsakov. 2017;2:28-42. (In Russ.).
Westergaard ML, Hansen EH, Glümer C, et al. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014;34(6):409-425.
Zeeberg P, Olesen J, Jensen R. Medication overuse headache and chronic migraine in a specialized headache centre: field-testing proposed new appendix criteria. Cephalalgia. 2009;29(2):214-220.
Steiner TJ, MacGregor EA, Davies PTG. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication overuse headache. British Association for the Study of Headache, 3rdedn. 2007.
Tepper SJ, Dahlöf CG, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache. 2004;44(9):856-864.
Reference programme: Diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition, 2012. J Headache Pain. 2012;13:1-29.
Lipton RB, Serrano D, Buse DC, et al. Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM). Cephalalgia. 2016;36(3):203-215.
Jiang H, Deng Y, Zhang Y, et al. Field testing of the ICHD-3β and expert opinion criteria for chronic migraine. J Headache Pain. 2016;17(1):85.
Lampl C, Buzath A, Yazdi K, Sandor PS. Ergot and triptan overuse in Austria — an evaluation of clinical data and cost. Cephalalgia. 2002;22:807-811.
Mitsikostas D, Ashina M, Craven A, et al. EHF committee. European headache federation consensus on technical investigation for primary headache disorders. J Headache Pain. 2015;17:5.
Kamtchum-Tatuene J, et al. Neuroimaging findings in headache with normal neurologic examination: Systematic review and meta-analysis. Journal of the Neurological Sciences. 2020;416:116997.
Kruit MC, van Buchem MA, Launer LJ, et al. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia. 2010;30(2):129-136.
Ekusheva EV. The many faces of female migraine. Moscow: MEDpress-inform; 2019. (In Russ.).
Mett A, Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr Opin Neurol. 2008;21(3):331-337.
Kindelan-Calvo P, Gil-Martínez A, Paris-Alemany A, et al. Effectiveness of therapeutic patient education for adults with migraine. A systematic review and meta-analysis of randomized controlled trials. Pain Med. 2014;15(9):1619-1636.
Mukhtar NB, Meeus M, Gursen C, Mohammed J, De Pauw R, Cagnie B. Effectiveness of hands-off therapy in the management of primary headache: a systematic review and meta-analysis. Eval Health Prof. 2021;163278720983408.
Kirthi V, Derry S, Moore R. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;4:CD008041.
Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol. 2007;254(6):705-712.
Rabbie R, Derry S, Moore RA, McQuay HJ. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;(10):CD008039.
Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;4:CD008039.
Suthisisang CC, Poolsup N, Suksomboon N, et al. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache. 2010;50(5):808-818.
Law S, Derry S, Moore RA. Naproxen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 2013;10:CD009455.
Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;4:CD008040.
Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;4:CD008783.
Diener HC, Montagna P, Gacs G, et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: A randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26:537-547.
Dib M, Massiou H, Weber M, Henry P, Garcia-Acosta S, Bousser MG; Bi-Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology. 2002;58(11):1660-1665.
Colman I, Brown MD, Innes GD, et al. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004;329(7479):1369-1373.
Kellstein DE, Lipton RB, Geetha R, et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: A randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia. 2000;20:233-243.
Cameron C, Kelly S, Hsieh SC, et al. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015;55(suppl 4):221-235.
Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633-658.
Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;CD008615.
Smith LA, Oldman AD, McQuay HJ, Moore RA. Eletriptan for acute migraine. Cochrane Database Syst Rev. 2001;CD003224.
Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication. A review. Cephalalgia. 2004;24:321-332.
Pascual J, Mateos V, Roig C, et al. Marketed oral triptans in the acute treatment of migraine: A systematic review on efficacy and tolerability. Headache. 2007;47:1152-1168.
Thorlund K, Mills EJ, Wu P, et al. Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta-analysis. Cephalalgia. 2014;34:258-267.
Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther. 2000;22(9):1035-1048.
Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. 2004;11:671-677.
Filatova EG, Amelin AV, Tabeeva GR, et al. Ready - the first Russian multicenter study of the efficacy of the drug relpax (eletriptan) in the treatment of migraine. Treatment of Nervous Diseases. 2006;2:19-22. (In Russ.).
Filatova EG, Osipova VV, Tabeeva GR, et al. Diagnosis and treatment of migraine: recommendations of Russian experts. Neurology, neuropsychiatry, psychosomatics. 2020;12(40):4-14. (In Russ.).
Taggart E, Doran S, Kokotillo A, Campbell S, Villa-Roel C, Rowe BH. Ketorolac in the treatment of acute migraine: a systematic review. Headache. 2013;53(2):277-287.
Orr SL, Aube’ M, Becker WJ, et al. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia. 2015;35:271.
Friedman BW, Mulvey L, Esses D, et al. Metoclopramide for acute migraine: a dose finding randomized clinical trial. Ann Emerg Med. 2011;57(5):475-482.
Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med. 2002;23(2):141-148.
Cameron JD, Lane PL, Speechley M. Intravenous chlorpromazine vs intravenous metoclopramide in acute migraine headache. Acad Emerg Med. 1995;2(7):597-602.
Turkcuer I, Serinken M, Eken C, et al. Intravenous paracetamol versus dexketoprofen in acute migraine attack in the emergency department: A randomised clinical trial. Emerg Med J. 2014;31:182-185.
Gungor F, Akyol KC, Kesapli M, et al. Intravenous dexketoprofen vs placebo for migraine attack in the emergency department: A randomized, placebo-controlled trial. Cephalalgia. 2016;36:179-184.
Bigal ME, Bordini CA, Tepper SJ, et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura: A randomized, doubleblind, placebo-controlled study. Cephalalgia. 2002;22:345-353.
Corbo J, Esses D, Bijur PE, et al. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med. 2001;38:621-627.
Cete Y, Dora B, Ertan C, et al. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the emergency department. Cephalalgia. 2005;25:199-204.
Friedman BW, Garber L, Yoon A, et al. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014;82:976-983.
Leniger T, Pageler L, Stude P, Diener HC, Limmroth V. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache. 2005;45:42-46.
Diener HC, Antonaci F, Braschinsky M, Evers S, Jensen R, Lainez M, Kristoffersen ES, Tassorelli C, Ryliskiene K, Petersen JA. European Academy of Neurology guideline on the management of medication-overuse headache. Eur J Neurol. 2020;27(7):1102-1116.
Woldeamanuel YW, Rapoport AM, Cowan RP. The place of corticosteroids in migraine attack management: a 65-year systematic review with pooled analysis and critical appraisal. Cephalalgia. 2015;35(11):996-1024.
Friedman BW, Greenwald P, Bania TC, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007;69:2038-2044.
Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: Meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008;336:1359-1361.
Neill A, Brannigan D. Towards evidence-based emergency medicine: Best BETs from the Manchester Royal Infirmary. BET 2: Dexamethasone for reduction of migraine recurrence. Emerg Med J. 2013;30:165-166.
Huang Y, Cai X, Song X, et al. Steroids for preventing recurrence of acute severe migraine headaches: A metaanalysis. Eur J Neurol. 2013;20:1184-1190.
Wang SJ, Silberstein SD, Young WB. Droperidol treatment of status migrainosus and refractory migraine. Headache. 1997;37:377-382.
Silberstein SD, Young WB, Mendizabal JE, et al. Acute migraine treatment with droperidol: a randomized, double-blind, placebo-controlled trial. Neurology. 2003;60(2):315-321.
Honkaniemi J, Liimatainen S, Rainesalo S, et al. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache. 2006;46(5):781-787.
Gaffigan ME, Bruner DI, Wason C, et al. A randomized controlled trial of intravenous haloperidol vs. intravenous metoclopramide for acute migraine therapy in the emergency department. J Emerg Med. 2015;49:326.
Balbin JEB, Nerenberg R, Baratloo A. Intravenous fluids for migraine: a post hoc analysis of clinical trial data. Am J Emerg Med. 2016;34:713-716.
Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21(4 Headache):973-989.
Jackson JL, Cogbill E, Santana-Davila R, et al. Comparative effectiveness meta-analysis of drugs for the pophylaxis of migraine headache. PLoS One. 2015;10(7):e0130733.
He A, Song D, Zhang L, Li C. Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. J Headache Pain. 2017;18(1):26.
Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28:484-495.
Silva-Néto RP, Almeida KJ, Bernardino SN. Analysis of the duration of migraine prophylaxis. J Neurol Sci. 2014;337(1-2):38-41.
Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia. 1984;4:91-96.
Steiner TJ, Joseph R, Hedman C, Rose FC. Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up. Headache. 1988;28(1):15-23.
Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2017;2(2):CD003225.
Chronicle EP, Mulleners WM. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev. 2016;5:CD003226.
Bussone G, Diener HC, Pfeil J, et al. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J ClinPract. 2005;59:961-968.
Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170-180.
Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;2013(6):CD010610.
Herd CP, Tomlinson CL, Rick C, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. 2018;6:CD011616.
Cady RK, Schreiber CP, Porter JA, et al. A multi-center double-blind pilot comparison of onabotulinumtoxin A and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;51(1):21-32.
Silberstein SD, Blumenfeld AM, Cady RK, et al. Onabotulinumtoxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331:48-56.
Negro A, Curto M, Lionetto L, Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1.
Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026-1037.
Dodick DW, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial. JAMA. 2018;319(19):1999-2008.
Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425-434.
Bigal M, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1081-1090.
Johannsson V, Nilsson LR, Widelius T, Jäverfalk T, Hellman P, Akesson JA, Olerud B, Gustafsson CL, Raak A, Sandahl G, et al. Atenolol in migraine prophylaxis a double-blind cross-over multicentre study. Headache. 1987;27(7):372-374.
Jackson JL, Shimeall W, Sessums L, et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010;341:5222.
Xu XM, Yang C, Liu Y, et al. Efficacy and feasibility of antidepressants for the prevention of migraine in adults: a meta-analysis. Eur J Neurol. 2017;24(8):1022-1031.
Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg. 2004;107:44-48.
Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005;45:144-152.
Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289:65-69.
Stovner LJ, Linde M, Gravdahl GB, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014;34(7):523-532.
Linde M, Mulleners WM, Chronicle EP, et al. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;6:CD010611.
Fritsche G, Frettloh J, Huppe M, et al. Prevention of medication overuse in patients with migraine. Pain. 2010;151:404-413.
Limmroth V, Biondi D, Pfeil J, et al. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache. 2007;47:13-21.
Rossi P, Di Lorenzo C, Faroni J, et al. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006;26:1097-1105.
de Goffau MJ, Klaver AR, Willemsen MG, et al. The effectiveness of treatments for patients with medication overuse headache; A systematicreview and meta-analysis. J Pain. 2017;18:615-627.
Hagen K, Albretsen C, Vilming ST, et al. Complete detoxification is the most effective treatment of medication-overuse headache: a randomized controlled open-label trial. Cephalalgia. 2018;38:225-236.
Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814-823.
Sandrini G, Perrotta A, Tassorelli C, et al. Botulinumtoxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind,randomized, placebo-controlled, parallel group study. J Headache Pain. 2011;12:427-433.
Silberstein SD, Ashina S, Katsarava Z, et al. The impact of fremanezumab on medication overuse in patients with chronic migraine. Headache. 2018;58:76-77.
Pazdera L, Ning X, Campos VR, et al. Efficacy of fremanezumab in patients with migraine and documented inadequate response to 3 or 4 migraine preventive medication classes and medication overuse in the international, multicenter, randomized placebo-controlled FOCUS study. Poster, 14th European Headache Federation Congress, 2020.
Tepper SJ, Diener HC, Ashina M, et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology. 2019;92:2309-2320.
Tassorelli C, Jensen R, Allena M, et al. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia. 2014;34:645-655.
Trucco M, Meineri P, Ruiz L, Gionco M. Medication overuse headache: withdrawal and prophylactic therapeutic regimen. Headache. 2010;50:989-997.
Zeeberg P, Olesen J, Jensen R. Efficacy of multidisciplinary treatment in a tertiary referral headache centre. Cephalalgia. 2005;25:1159-1167.
Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia. 2006;26:1192-1198.
Munksgaard SB, Bendtsen L, Jensen RH. Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: acomparison of two consecutive treatment methods in an open-label design. Cephalalgia. 2012;32:834-844.
Carlsen LN, Munksgaard SB, Jensen RH, et al. Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial. Cephalalgia. 2018;38:225-236.
Buse DC, et al. Migraine progression: a systematic review. Headache: The Journal of Head and Face Pain. 2019;59(3):306-338.
Probyn K, et al. Prognostic factors for chronic headache: a systematic review. Neurology. 2017;89(3):291-301.
Chiang CC, et al. Treatment of medication-overuse headache: a systematic review. Cephalalgia. 2016;36(4):371-386.
Pageler L, Katsarava Z, Diener HC, et al. Prednisone vs. placebo in withdrawal therapy following medication overuse headache. Cephalalgia. 2008;28:152-156.
Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic induced daily headache. Cephalalgia. 2000;20:107-113.
Fiesseler FW, Shih R, Szucs P, et al. Steroids for migraine headaches: a randomized double-blind, twoarmed, placebo-controlled trial. J Emerg Med. 2011;40:463-468.
Rabe K, Pageler L, Gaul C, et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2013;33:202-207.
Cevoli S, Giannini G, Favoni V, et al. Treatment of withdrawal headache in patients with medication overuse headache: a pilot study. J Headache Pain. 2017;18(1):56.
Paolucci M, Altamura C, Brunelli N, et al. Methylprednisolone plus diazepam i.v. as bridge therapy for medication overuse headache. Neurol Sci. 2017;38(11):2025-2029.
Trucco M, Meineri P, Ruiz L. «Gruppo Neurologico Ospedaliero Interregionale per lo Studio delleCefalee» (Neurological Hospital Interregional Group for the Study of Headache). Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache. J Headache Pain. 2005;6(4):334-337.
Taghdiri F, Togha M, Razeghi JS, Paknejad SM. Celecoxib vs prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind clinical trial. Headache. 2015;55(1):128-135.
Luedtke K, Allers A, Schulte LH, et al. Efficacy of interventions used by physiotherapists for patients with headache and migraine. Systematic review and meta-analysis. Cephalalgia. 2016;36(5):474-492.
Millstine D, Chen CY, Bauer B. Complementary and integrative medicine in the management of headache. BMJ. 2017;357:j1805.
Giannitrapani K, Holliday J, Miake-Lye I, et al. Synthesizing the strength of the evidence of complementary and integrative health therapies for pain. Pain Med. 2019;pii: pnz068.
Lee HJ, Lee JH, Cho EY, et al. Efficacy of psychological treatment for headache disorder: a systematic review and meta-analysis. J Headache Pain. 2019;20(1):17.
Anheyer D, Leach MJ, Klose P, et al. Mindfulness-based stress reduction for treating chronic headache: A systematic review and meta-analysis. Cephalalgia. 2019;39(4):544-555.
Probyn K, Bowers H, Mistry D, et al. Non-pharmacological self-management for people living with migraine or tension-type headache: a systematic review including analysis of intervention components. BMJ Open. 2017;7(8):e016670.
Harris P, Loveman E, Clegg A, et al. Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults. Br J Pain. 2015;9(4):213-224.
Golovacheva V, Parfenov V, Tabeeva G, et al. Multidisciplinary integrated headache treatment program: results and identification of factors that influence treatment response. Eur J of Neurol. 2016;23(suppl 1):536.
Nestoriuc Y, Martin A. Efficacy of biofeedback for migraine: a meta-analysis. Pain. 2007;128(1-2):111-127.
Nestoriuc Y, Martin A, Rief W, Andrasik F. Biofeedback treatment for headache disorders: a comprehensive efﬁcacy review. Appl Psychophysiol Biofeedback. 2008;33:125-140.
Naprienko MV, Safonov MI, Smekalkina LV. Results of classical corporate acupuncture in the complex treatment of chronic migraine. Chiropractic therapy. 2017;4(68):96-99. (In Russ.).
Yin Jiang, Peng Bai, Hao Chen, et al. The Effect of Acupuncture on the Quality of Life in Patients With Migraine: A Systematic Review and Meta-Analysis. Front Pharmacol. 2018;9:1190.
Feng-Jiao Shen, Jia Xu, Yi-Jun Zhan, et al. Acupuncture for migraine: A systematic review and meta-analysis. World Journal of Acupuncture — Moxibustion. 2019;29(1):7-14.
Falsiroli ML, Geri T, Gianola S, et al. Effectiveness of trigger point manual treatment on the frequency, intensity, and duration of attacks in primary headaches: asystematic review and meta-analysis of randomized controlled trials. Front Neurol. 2018;9:254.
Lemmens J, De Pauw J, Van Soom T, et al. The effect of aerobic exercise on the number of migraine days, duration and pain intensity in migraine: a systematic literature review and meta-analysis. J Headache Pain. 2019;20(1):16.
Krøll LS, Hammarlund CS, Linde M, et al. The effects of aerobic exercise for persons with migraine and co-existing tension-type headache and neck pain. A randomized, controlled, clinical trial. Cephalalgia. 2018;38(12):1805-1816.
Cuadrado ML, Aledo-Serrano Á, Navarro P, et al. Short-term effects of greater occipital nerve blocks in chronic migraine: a double-blind, randomised, placebo-controlled clinical trial. Cephalalgia. 2017;37:864-872.
Allen SM, Mookadam F, Cha SS. Greater occipital nerve block for acute treatment of migraine headache: a large retrospective cohort study. J Am Board Fam Med. 2018;1(2):211-218.
Misra UK, Kalita J, Bhoi SK. High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: a randomized, placebo-controlled study. J Neurol. 2013;260(11):2793-2801.
Lan L, Zhanq X, Li X, et al. The efficacy of transcranial magnetic stimulation on migraine: a meta-analysis of randomized controlled trails. J Headache Pain. 2017;18(1):86.
Conforto AB, Amaro E Jr, Gonçalves AL, et al. Randomized, proof-of-principle clinical trial of active transcranial magnetic stimulation in chronic migraine. Randomized controlled trial. Cephalalgia. 2014;34(6):464-472.
Stilling JM, Monchi O, Amoozegar F, Debert CT. Transcranial magnetic and direct currents (TMS/tDCS) for the treatment of headache: a systematic review. Headache. 2019;59(3):339-357.
Chou D, Yugrakh M, Winegarne D, et al. Acute migraine therapy with external trigeminal neurostimulation ACME: A randomized controlled trial. Cephalalgia. 2019;39(1):3-14.
Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator. A-randomized-controlled-trial. Neurology. 2013;80:697-704.
Miller S, Sinclair AJ, Davies B, et al. Neurostimulation in the treatment of primary headaches. Pract Neurol. 2016;16(5):362-375.
Cadalso RT, Daugherty J, Holmes C, et al. Efficacy of Electrical Stimulation of the Occipital Nerve in Intractable Primary Headache Disorders: A Systematic Review with Meta-Analyses. J Oral Facial Pain Headache. 2018;32(1):40-52.
Yang Y, Song M, Fan Y, Ma K. Occipital Nerve Stimulation for Migraine: A Systematic Review. Pain Pract. 2016;16(4):509-517.
Deer T, Levy R, Diaz RL, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012;32(16):1165-1179.
Isagulian ED, Ekusheva EV, Artemenko AR, et al. Neuromodulation in the treatment of primary forms of headache: mechanisms of effectiveness, review of methods and indications for use. Russian Journal of Pain. 2018;3(57):5-15. (In Russ.).
Osipova VV, Ekusheva EV, Isagulian ED, et al. Invasive neuromodulation in the treatment of refractory forms of migraine and cluster headache: patient selection criteria and review of effectiveness. Russian Journal of Pain. 2019;17(1):9-16. (In Russ.).
Price DD, et al. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983.
Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011;63(suppl 11):240-252.
Chiarotto A, Maxwell LJ, Ostelo RW, Boers M, Tugwell P, Terwee CB. Measurement Properties of Visual Analogue Scale, Numeric Rating Scale, and Pain Severity Subscale of the Brief Pain Inventory in Patients With Low Back Pain: A Systematic Review. J Pain. 2019;20(3):245-263.